Molecular diagnostics is still a relatively new opportunity in the clinical diagnostics space - about $4 billion/year if Roche's (OTCQX:RHHBY)
estimates of its market share are accurate. It remains a good growth
opportunity, though, as molecular diagnostic technologies can in many
cases offer faster and more accurate results for healthcare providers. GenMark Diagnostics (NASDAQ:GNMK)
is looking to emerge as a leader in hospital/lab-based multiplex
molecular diagnostics with a new system (ePlex) designed to deliver fast
and accurate results with good throughput.
GenMark's existing
business isn't going to take the business very far, so a great deal is
riding on that new system. The performance specs look very competitive,
but rivals aren't going to back it in and give up. This remains an
exceptionally speculative story, but one with worthwhile upside from
here if the 2015 launch goes well. While the stock has been weak since my last article (along with many other riskier med-tech stories), I think the name is still worth consideration.
Continue reading here:
GenMark Diagnostics Hoping To Make Its Mark In Clinical MDx
No comments:
Post a Comment